The U.S. Blood System: Under Pressure
Dr. Menitove discusses obstacles and pressure on U.S. blood centers and the U.S. blood supply.
Targeted Therapy to Trigger GVL: A Case for the Prosecution in FLT3-ITD–Mutant AML
Dr. Roberts sheds light on a mechanism by which a small molecule inhibitor targeting a leukemia-specific kinase mutation can trigger an effective CD8 T cell-mediated allo-i
In his final President's Column, Dr. Abrams sheds light on the many great accomplishments ASH has achieved during 2016 as well as important initiatives on the horizon that ASH members have made possible this year.
Dr. Abrams talks about the importance of ASH's effort to promote diversity through its Minority Recruitment Initiative's programs.
Dr. Abrams talks about the ASH executive committee's experience in Havana, Cuba during this year's retreat.
Dr. Charles Abrams discusses the "National Cancer Moonshot" which covers advancements in cancer therapy that are currently underway and ASH's efforts in influencing this dialogue.
Dr. Abrams discusses the media efforts ASH engages in to spread awareness about hematologic breakthroughs and developments.
In his first President's Column, Dr. Abrams sheds light on the meaningful ways in which ASH is a leader in hematology and sets the stage for how ASH can continue to expand outreach and growth on a global scale in 2016.
Dr. Charles Abrams discusses his views on the safety and efficacy of novel oral anticoagulants.
On November 17, 2010, we lost one of our most distinguished and beloved colleagues, Dr. Alan M. Gewirtz. Alan dedicated his career to the development of novel therapeutics for the treatment of leukemia. He was the C. Willard Robinson Professor in Medicine and Pathology at the University of Pennsylvania (Penn) and headed the Hematologic Malignancy Program at the Abramson Cancer Center.
As a hematologist, and the recently elected Chair of the American Board of Internal Medicine (ABIM) Hematology Board, I thought I would explain what is required to remain board certified in our subspecialty. Although maintaining ABIM certification is not mandatory, it is an important marker of standard training and professional and clinical competence.
Soon after William Harvey described the circulation of blood in the early 17th century, Christopher Wren unsuccessfully experimented with replacing wine for blood. During a cholera outbreak in the late 19th century, Gaillard Thomas also failed in his attempts to substitute milk for blood. It was not until 1933 that the first successful blood substitution experiments were performed.
May-June 2018Volume 15, Issue 3
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology